ICCC logo

ImmuCell Corp

ICCC

Build a strategy around ICCC

Accountable AI Logo

ImmuCell Corp AI Insights

Informational only. Not investment advice.
As of 2026-01-21

Snapshot

  • Positive operating income (2.3M TTM, 8.4% margin) vs industry median of -20M - rare profitability in biotech/pharma sector[Operating Income TTM]
  • Inventory at 9.8M (58% of current assets) with 35% of revenue tied up - potential obsolescence or demand mismatch risk[Inventory]
  • R&D at 3.1M TTM (11% of revenue) while maintaining profitability - disciplined spend vs peers burning cash[Research and Development TTM]

Watch Triggers

  • Inventory: Exceeds 40% of revenue or grows faster than salesCurrent 35% of revenue already elevated; further buildup signals demand issues
  • Operating Margin TTM: Falls below 5%Thin margin buffer; small revenue miss could flip to losses
  • Long Term Debt: Increases above 15M or refinancing at higher rates11.9M debt at current rates manageable; higher rates pressure thin FCF

Bull Case

One of few profitable small-cap pharma names: ROE 8.3%, ROA 5.2%, ROIC 5.4% TTM - all positive vs deeply negative industry medians (-40%, -31%, -32%)

ROE TTMROA TTMROIC TTM

Asset-heavy model (PP&E 28.8M, 63% of assets) creates barriers; now cash flow positive (2.0M CFO, 715K FCF TTM) after capex cycle

PP&ECash Flow TTMFree Cash Flow TTM

Bear Case

Micro-cap (61.5M market cap) with 11K daily volume - illiquid, wide spreads, difficult to exit positions at scale

Market Cap TTMVolume

P/E of 28.4x vs industry median 20.6x - premium valuation for a company with sub-30M revenue and limited growth runway

PE RatioTotal Revenue TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
45%

Leverage ICCC's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Margin expansion likely as fixed cost leverage improves on 8% 5Y revenue CAGR

1-3ymed
  • Operating margin 8.4% with room to scale
  • PP&E of 28.8M now generating positive returns
  • Interest expense (461K) manageable at 0.46 D/E
Net margin 8.4% vs industry median 0%5Y revenue growth 8.1% vs median 7.5%ROIC 5.4% vs median -32%

Valuation Context

Caveats

Public Strategies Rankings

See how ImmuCell Corp ranks across different investment strategies.

Leverage ICCC's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.